Triple-positive profile may flag adverse prostate cancer pathology - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Triple-positive profile may flag adverse prostate cancer pathology

A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.

  • By

  • Andrea Surnit

  • September 8, 2026

  • 4 min

Share

Clinical Scorecard: Triple-positive profile may flag adverse prostate cancer pathology

At a Glance

CategoryDetail
ConditionProstate Cancer
Key MechanismsCombination of prostate-specific antigen density, multiparametric MRI, and PSMA PET/CT findings
Target PopulationPatients undergoing radical prostatectomy for prostate cancer
Care SettingRetrospective evaluation in a single-center study

Key Highlights

  • 60% of patients had adverse pathology at radical prostatectomy.
  • Adverse pathology rates increased with higher PSAD and PI-RADS scores.
  • The triple-positive profile showed 100% specificity and positive predictive value.
  • Only 22 patients met all three criteria for the triple-positive profile.
  • The study suggests further investigation into biopsy-sparing strategies.

Guideline-Based Recommendations

Diagnosis

  • Evaluate prostate-specific antigen density, mpMRI, and PSMA PET/CT findings.

Management

  • Consider the triple-positive profile for prospective studies of biopsy omission.

Monitoring & Follow-up

  • Monitor patients with PSAD, PI-RADS, and SUVmax findings.

Risks

  • Potential for selection bias and unmeasured confounding due to retrospective design.

Patient & Prescribing Data

413 patients who underwent radical prostatectomy between December 2015 and December 2024.

Biopsy provides important histologic information for treatment planning.

Clinical Best Practices

  • Use combined clinical and imaging predictors for assessing adverse pathology.
  • External validation of proposed criteria is warranted before adoption.

Related Resources & Content

Original Source(s)

Triple-positive profile may flag adverse prostate cancer pathology

  • by Andrea Surnit

  • September 8, 2026

Related Content

Consensus Guidance May Improve Sinonasal Mass Outcomes

Multidisciplinary recommendations emphasize biopsy technique, imaging, and pathology review in patients with suspected sinonasal malignancy.

FDA Approves Melanoma BRAF Companion Test

The assay is indicated to identify patients with advanced melanoma who have BRAF V600E or BRAF V600K variants and may benefit from FDA-approved targeted therapies.

Side Effects: Progress, with Asterisks

Burnout is easing. Sleep science is getting weird. And dental schools have been winging cadaver training for 50 years. This week's research is full of good news that immediately complicates itself.